3nt Medical Ltd.

DUBLIN, March 10, 2023 /PRNewswire/ -- The "Innovations and Growth Opportunities in Cardiac Implants, Wound Care, MRI and Organ Transplant Technologies" report has been added to ResearchAndMarkets.com's offering. The latest issue of Advanced MedTech Technology Opportunity Engine (TOE) profiles a wide range of innovations from the advanced medical device and imaging industry. The issue includes advanced technologies in cardiac implants including heart failure monitoring implanted sensor, heart neuromodulator, mitral valve repair and aortic patch. Novel transplant diagnostic and perfusion technologies have also been covered in this issue. Advances in magnetic resonance imaging (MRI) such as wearable metamaterial MRI or AI enabled MRI and wound care technologies such as cell therapy, electroceutical wound dressing are included in this issue. These innovations portray the diversity in their technology readiness levels, indicating an immediate or potential market impact. The growth opportunities for all these advanced medical device technologies are also covered in this issue. The Advanced MedTech TOE analyzes and reports new and emerging technologies; advances in R&D, product development and regulatory matters specifically related to the areas of wearables, implantable, diagnostics, surgical tools and instrumentation, image guided surgery, drug delivery, patient monitoring, digital health, and medical imaging. Medical devices and imaging technology and innovation research covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies, and imaging technologies and platforms. Medical devices and imaging technology and innovation research covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies, and imaging technologies and platforms. Medical devices and imaging technology and innovation research covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies, and imaging technologies and platforms. Medical devices and imaging technology and innovation research covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies, and imaging technologies and platforms. Key Topics Covered: 1 Innovations in Medical Devices and Imaging Artificial Intelligence (AI)-driven Chatbot For Mental Health Support Wysa's Value Proposition Wysa: Investor Dashboard Nanoparticle-based Drug-coated Balloon Delivering Sirolimus and Paclitaxel NanoTherapies's Value Proposition Advanced NanoTherapies: Investor Dashboard Normothermic Perfusion for Ex-vivo Organ Preservation EBERS Medical Technology's Value Proposition EBERS Medical Technology: Investor Dashboard Rapid And Non-invasive Organ Rejection Detection Diagnostic Plexision's Value Proposition Plexision: Investor Dashboard Sequencing-based Rapid Histocompatibility Assessment for Pre-Transplant Diagnosis Value Proposition of Omixon Biocomputing Omixon Biocomputing: Investor Dashboard Wireless Wearable Metamaterial MRI Device to Reduce Scan Times and Improve Diagnosis Multiwave Imaging's Value Proposition Multiwave Imaging - Investor Dashboard Miniature, Wireless, and Battery-free In-heart Sensor for Monitoring Left Atrial Pressure (LAP) Value Proposition of Vectorious Medical Technologies Vectorious Medical Technologies - Investor Dashboard Single-use Sinus Endoscope to View Deep Intra-Sinus Anatomy Value Proposition of 3NT Medical 3NT Medical - Investor Dashboard AI-powered Magnetic Resonance Imaging (MRI) Reconstruction Software for High-quality Images Value Proposition of AIRS Medical Inc. AIRS Medical Inc. - Investor Dashboard Point-of-care AI-enabled Wearable Device for Joint Health Assessment Value Proposition of Sensemodi Sensemodi - Investor Dashboard Cell Therapy for Repairing Cardiac Damage Due to Myocardial Infarction Metcela - Value Proposition Metcela - Investor Dashboard Neuromodulator Device Stimulating Carotid Baroreceptors to Treat Heart Failure CVRx - Value Proposition CVRx - Investor Dashboard Indirect Mitral Annuloplasty for Treating Mitral Regurgitation Cardiac Dimensions - Value Proposition Cardiac Dimensions - Investor Dashboard Catheter-based Biomimetic Patch for Treating Aortic Dissection Aortyx's Value Proposition Aortyx - Investor Dashboard Catheter-based Procedure for Pressure Restoration in Aortic Stenosis Pi-Cardia's Value Proposition Pi-Cardia - Investor Dashboard Autologous Cellular Therapy for Burn Wound Healing RenovaCare, Inc. - Value Proposition RenovaCare, Inc. - Investor Dashboard Electroceutical Wound Dressing with Broad-spectrum Antimicrobial Impact Vomaris Innovations - Value Proposition Vomaris Innovations - Investor Dashboard Electrical Impedance Demography (EID)-based Portable Device for Diagnosing Basal and Squamous Cell Skin Cancer The University of Utah's Value Proposition AI-based Smartphone Application for Detecting Parkinson's Disease RMIT University - Value Proposition 2 Key Contacts 3 Appendix Criteria for Rating of Innovations - Explanation Legal Disclaimer A selection of companies mentioned in this report includes Wysa NanoTherapiesn EBERS Medical Technology Plexision Omixon Biocomputing Vectorious Medical Technologies 3NT Medical AIRS Medical Inc. Sensemodi Sensemodi Metcela CVRx Cardiac Dimensions Aortyx Pi-Cardia RenovaCare, Inc. Vomaris Innovations The University of Utah RMIT University For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Peregrine is suitable for use alongside the traditional 0° rigid endoscope or as the main endoscope in the operating room The FDA has approved 3NT Medical’s single-use Peregrine sinus endoscope. (Credit: Business Wire) 3NT Medical has secured approval from the US Food and Drug Administration (FDA) for its Peregrine Drivable ENT Scope. The new single use sinus endoscope will enable ENT surgeons to access and view deep intra-sinus anatomy with minimal resection. The device allows to visualise anatomic landmarks up-close with enhanced image quality and minimal resection, both intra and post-operatively. Its novel mechanics helps the surgeon to angulate the device’s 2.3mm tip sharply, as well as then advance it further in the direction of the turn and all through single-hand operation. Peregrine is suitable for use alongside the traditional 0° rigid endoscope, or as the main endoscope in the operating room. The small-footprint video console to which Peregrine is linked negates the need for bulky and expensive endoscopy towers that traditional endoscopes require, said the company. According to the company, Peregrine was able to view 100% of the frontal and sphenoid sinuses and 97.1% of the maxillary sinus compared to 45.3%, 53.3% and 39.4% for 4mm rigid endoscopes ranging from 0° to 70°. 3NT Medical CEO Ehud Bendory said: “Assessing the sinuses from a distance is now a thing of the past with Peregrine. This new scope joins our commercially-available Colibri Micro ENT Scope for otologists, and demonstrates that 3NT Medical is executing on its vision of creating a portfolio of endoscopes designed specifically for ENT use. “We designed Peregrine exclusively for ENT surgeons to enable a better surgical experience for them as they strive to provide better outcomes and an enhanced experience for their patients.” 3NT Medical is engaged in the development of endoscopic solutions for otorhinolaryngology applications across the world.

Boston Scientific (NYSE:BSX) announced today that it received FDA 510(k) clearance for its Exalt Model B single-use bronchoscope. Marlborough, Mass.-based Boston Scientific designed the Exalt Model B for use in bedside procedures within the intensive care unit and operating room, according to a news release. Uses for the device include a wide range of bronchoscopy procedures, including secretion management, airway intubation, percutaneous tracheostomy, double-lumen endotracheal tube placement and biopsies. The FDA also cleared 3NT Medical’s Peregrine Drivable ENT scope as a single-use endoscope that gives ENT surgeons views of the sinus anatomy. According to a news release, Boston Scientific offers the device in three sizes — slim, regular and large — with each sizing designed to offer superior suction performance and direct, precise imaging. Exalt Model B joins the Exalt Model D single-use duodenoscope, the LithoVue digital flexible ureteroscope, the SpyGlass DS direct visualization system and the SpyGlass Discover digital catheter. Exalt Model B received CE mark approval in May and Boston Scientific plans to begin the limited market release of the platform in the U.S. within the coming weeks. “To further increase patient safety and improve operational efficiencies within the hospital setting, many physicians have been making the transition to single-use scopes, which eliminate both the risk of infection associated with reusable devices, as well as time-intensive scope reprocessing,” Boston Scientific EVP, president of medsurg & president of endoscopy Dave Pierce said in the release. “Developed with physician needs and varying patient anatomies in mind, the EXALT Model B Bronchoscope was designed to bring a new level of suction and imaging performance to single-use scopes and offers a familiar design and feel to that of a reusable device.”